Conversion Disorder Clinical Trial
Official title:
TMS and Attentional Bias in Functional Motor Disorder
Functional motor disorders, also called motor conversion disorder, are common reasons for
attendance at neurology outpatient clinics. Patients with functional motor disorders are
more common than patients with multiple sclerosis and have similar levels of disability but
more psychological morbidity.
There is limited evidence for effective treatments in functional motor disorders. A small
number of studies of transcranial magnetic stimulation (TMS), a painless method of cortical
stimulation, have reported improvement in functional weakness after this treatment including
in patients with symptoms of several years duration. The Investigators intend to trial TMS
in a group of 40 patients with functional motor disorder, randomising patients to immediate
or delayed treatment and therefore comparing a single session of TMS with routine clinical
care. The Investigators will also ask patients to undergo tests of attentional focus in a
cognitive neuroscience laboratory - these experiments will be analysed separately from TMS
trial data.
A randomised non-blinded controlled study design will be used, with 3 months of treatment as
usual as the control condition and a single session of TMS as the treatment condition.
40 patients with functional unilateral upper limb weakness will be recruited from neurology
and neuropsychiatry clinics in Edinburgh and randomised to either immediate treatment or to
3 month delay during which they will receive routine clinical care. Randomisation will be
performed using computerised random number generator by a person not involved with the
study.
Patients randomised to delay will complete baseline measures of disability and motor
function including SF36, modified Rankin score and study specific questionnaires, and will
repeat these after 3 months. Patients undergoing immediate treatment will complete the same
questionnaires immediately before and 3 months after treatment. All individuals receiving
TMS treatment will undergo tests of grip strength and tapping frequency immediately before
and after treatment.
The treatment and experiments involved will be as follows. Patients will attend the PPLS
Cognitive Neuroscience Laboratory at George Square, University of Edinburgh for a single 2
hour session. During the first hour they will complete baseline symptom severity and
disability questionnaires and will undertake a series of 3 experiments. Experiments involve
participants sitting with their head on a chin-rest looking at either a computer screen or
at lights projected onto their own hands, and for one experiment with a vibrating 'buzzer'
taped to each hand. They will be asked to respond verbally in experiments which test their
response to distracting attentional 'cues' either visual or vibrotactile. These experiments
will take less than 1 hour. In anaylsis, performance will be compared between affected and
unaffected sides (ie left hand and right hand), and will also be compared with performance
of a group of 15 healthy control participants recruited from spouses or partners.
Patient participants will then receive treatment with 20 single pulses of TMS to the motor
cortex at 120% motor threshold. These will cause visible and palpable 'jerks' of the
affected limb. Between stimulations the researcher will offer verbal encouragement and ask
the participant to move the affected limb if possible. Treatment will take less than 1 hour.
The primary outcome measures are patient-rated symptom severity and disability and simple
statistical analysis will be used to compare outcome after 3 months of treatment as normal
and 3 months after a single session of TMS treatment. Secondary outcome measures include
grip strength and tapping frequency before and after treatment. Data will be analysed on an
intention-to-treat basis. Data from attentional tests will be analysed separately.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02275000 -
Feasibility Study of Physiotherapy for Functional Motor Symptoms
|
N/A | |
Completed |
NCT00971360 -
Cytokine Levels in Conversion Disorder
|
N/A | |
Completed |
NCT00835627 -
Treatment Trial for Psychogenic Nonepileptic Seizures
|
Phase 4 | |
Active, not recruiting |
NCT01422278 -
Rehabilitation of Conversion Gait Disorder
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03441867 -
Neuroimaging Biomarker for Seizures
|
N/A | |
Completed |
NCT03398070 -
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
|
||
Completed |
NCT02325544 -
Comparing Different Treatments in Reducing Dissociative Seizure Occurrence
|
N/A | |
Terminated |
NCT02764476 -
Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder
|
N/A | |
Recruiting |
NCT05323344 -
Metacognitive Therapy and Neuro-physiotherapy as a Treatment for Functional Movement Disorders
|
N/A | |
Recruiting |
NCT04097184 -
Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients
|
N/A | |
Completed |
NCT05219006 -
Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures
|
N/A | |
Completed |
NCT02329626 -
Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
|
||
Recruiting |
NCT05943652 -
Observational Study on "Functional Overlay" in Patients With Movement Disorders
|
||
Completed |
NCT00159965 -
Treatments for Psychogenic Nonepileptic Seizures (NES)
|
Phase 4 | |
Completed |
NCT05305014 -
Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder
|